Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.
Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, de Frutos PG, Reig M, Fernandez-Checa JC, Marí M, Colell A, Bruix J, Morales A.
Tutusaus A, et al. Among authors: mari m.
Oncotarget. 2018 Mar 30;9(24):16701-16717. doi: 10.18632/oncotarget.24673. eCollection 2018 Mar 30.
Oncotarget. 2018.
PMID: 29682179
Free PMC article.